Cephalon Articles
Stock Commentary - Europe
10 November 2003
Victor Raczkowski named VP, regulatory affairs, at Cephalon
27 October 2003
Cephalon on track to expand Provigil label
27 October 2003
Cima reveals another takeover offer
27 October 2003
Stock Commentary - New York
18 August 2003
Cephalon product sales leap 147%
18 August 2003
Stock Commentary - New York
14 July 2003
Stock Commentary - New York
23 June 2003
Cephalon prices $600M offering
16 June 2003
Cephalon misses targets in first quarter
19 May 2003
"Bleak future for Australian biotech"
28 April 2003
Cephalon files patent suits over generic Provigil
7 April 2003
Lunbeck acquires Synaptic in $122M deal
17 March 2003
Lunbeck acquires Synaptic in $122M deal
17 March 2003
Stock Commentary - New York
3 March 2003
Pfizer takes on India's Ranbaxy over Lipitor
3 March 2003
Cephalon swings to profit in 4th quarter
3 March 2003
Cephalon makes $161 bid for SIRTeX
17 February 2003
Cephalon in discovery pact with MDS
20 January 2003
Round-up of pharmaceutical mergers and acquisitions during 2001
13 January 2003
FDA filings in brief
6 January 2003
Cephalon turnover rockets in 2nd quarter
12 August 2002
Lundbeck, Cephalon to trial Parkinson's drug
12 August 2002
Cephalon enters Transtech alliance
1 July 2002
Cephalon's sales grow 134%; losses down
20 May 2002
Stock Commentary - New York
22 April 2002
Sanofi-Synthelabo 2001 EPS leap 44%
25 February 2002
Stock Commentary - New York
11 February 2002
Alan Aragues joins Lab Lafon
28 January 2002
Cephalon gets more rights to Gabitril
14 January 2002
Cephalon completes Lafon acquisition
7 January 2002
Stock Commentary - Europe
7 January 2002
Cephalon sets up sales JV
7 January 2002
Cephalon completes Lafon acquisition
31 December 2002
Cephalon sets up sales JV
21 December 2001
Sanofi-Synthelabo and Cephalon to develop angiogenesis inhibitors
20 December 2001
Cephalon places $500 million in notes
7 December 2001
Stock Commentary - New York
11 October 2001
Stock Commentary - New York
16 August 2001
Promising results for Cephalon's Provigil
14 June 2001
Stock Commentary - New York
10 May 2001
Stock Commentary - New York
19 April 2001
Cephalon appointment
15 March 2001
Stock Commentary - New York
4 January 2001
Novartis ties up with Cephalon in UK marketing pact
7 December 2000
Abbott gives up US Gabitril rights
3 November 2000
Anesta wins approval for Actiq in UK
12 October 2000
Stock Commentary New York
3 August 2000
No ADHD benefit with Cephalon's Provigil
1 August 2000
Cephalon to acquire Anesta in $444M deal
18 July 2000
Stock Commentary New York
2 March 2000
Orphan Medical looks to future with Xyrem
27 January 2000
Appointments at Cephalon
5 January 2000
Cephalon and Schwarz link up in oncology
21 December 1999
Stock Commentary New York
18 November 1999
Stock Commentary New York
11 October 1999
Cephalon and Lundbeck commence Ph I CEP-1247 trials
29 July 1999
Stock Commentary New York
15 July 1999
Stock Commentary New York
24 June 1999
Management Changes at Cephalon
17 June 1999
Stock Commentary New York
17 June 1999
Cephalon to comarket Gabitril in USA
15 June 1999
Stock Commentary New York
10 June 1999
Lundbeck fills pipeline, signs CNS deals
1 June 1999
Cephalon starts Provigil trials
29 April 1999
Stock Commentary New York
14 April 1999
Cephalon launches Provigil in USA
18 February 1999
Stock Commentary New York
18 February 1999
FDA approves another generic Zantac
4 February 1999
Stock Commentary New York
7 January 1999
FDA approves Provigil for narcolepsy
29 December 1998
Myotrophin Dossier Withdrawn In EU
17 September 1998
Stock Commentary New York
10 September 1998
Battle On As Biotech Looks For New Ways Of Funding
8 September 1998
Stock Commentary New York
20 August 1998
Stock Commentary New York
12 August 1998
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- Neovacs moving forward in rheumatoid arthritis, say analysts
